Cellectis's André Choulika, Ph.D., Cellectis’ Chairman and CEO, announced that he will focus all his energy on Cellectis’ development activities, and thus, announced his retirement from Calyxt’s Board of Directors, effective immediately. Calyxt’s Board of Directors has appointed Yves Ribeill, Ph.D., currently a Calyxt Board member, as Chairman, effective immediately. Additionally, Calyxt’s Board of Directors appointed Laurent Arthaud, Cellectis’ Board member, as a Cellectis designated Director, effective immediately. Yves Joseph Ribeill, Ph.D., founded SCYNEXIS Inc. and served as President and CEO from 1999 to 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases including bacterial, fungal, viral and parasiticidal and in microbiome-centric diseases. In addition, the Calyxt Board of Directors appointed Laurent Arthaud, a member of Cellectis’ Board of Directors since 2011, as Director. Mr. Arthaud was designated to serve as a director by Cellectis, Calyxt’s parent company, pursuant to an existing Stockholders Agreement between Calyxt and Cellectis.